Pure Global AI
NCT06070246Not yet recruiting

Navigating the Clinical Research Process for Lymphoma

Gaining Insights Into Patient Involvement Patterns and Trends in Participation in Lymphoma Clinical Trials
Power Life Sciences Inc.ClinicalTrials.gov
Verified
Study focus
Disease/Condition
Lymphoma
Study type
Observational
Sponsor & location
Primary sponsor
Power Life Sciences Inc.
Location
San Francisco, United States of America
Timeline & enrollment
Phase
N/A
Start date
Oct 01, 2024
End date
Oct 01, 2026
Enrollment
500 participants
Primary outcome

Rate of patients who decide to enroll in a lymphoma clinical research.,Number of lymphoma study participants who remain in clinical study until completion.

Summary

Participation in medical research usually favors a particular demographic group. But there is
 limited research available to explain what trial attributes affect the completion of these
 specific demographic groups.
 
 This trial will admit a wide range of data on the clinical trial experience of lymphoma
 patients to determine which factors prevail in limiting a patient's ability to join or finish
 a trial.
 
 It will also try to analyze data from the perspective of different demographic groups to
 check for recurring trends which might yield insights for the sake of future lymphoma
 patients.

ICD-10 classifications
Hodgkin lymphomaFollicular lymphomaNon-Hodgkin lymphoma, unspecifiedFollicular lymphoma, unspecifiedHodgkin lymphoma, unspecified
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06070246
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06070246 through Pure Global AI's free database. This phase not specified trial is sponsored by Power Life Sciences Inc. and is currently Not yet recruiting. The study focuses on Lymphoma. Target enrollment is 500 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.